Sumitomo Chemical (SOMMF) Earnings Preview: EPS Seen at -$0.12 on Margin Pressure

Sumitomo Chemical Company, Limited (SOMMF) reports earnings on May 14, 2026, with analysts expecting a challenging quarter. The chemical giant faces headwinds as EPS estimates sit at negative $0.12, a significant shift from recent quarters. Revenue is projected at $3.88 billion, reflecting modest growth in a competitive chemicals market. The company’s diversified portfolio spans essential chemicals, energy materials, IT-related chemicals, and pharmaceuticals. With a market cap of $5.53 billion and trading at $3.375, investors will scrutinize profitability trends and operational efficiency. This earnings preview examines what to expect and how SOMMF’s performance compares to historical patterns.

Earnings Estimates and Revenue Outlook

Analysts expect SOMMF to report negative earnings per share of $0.12 for this quarter. This marks a notable deterioration from the prior quarter’s actual EPS of $0.1859, signaling margin compression or operational challenges. Revenue estimates of $3.88 billion represent a modest decline from the previous quarter’s $3.90 billion in actual revenue.

EPS Estimate Analysis

The negative EPS forecast is concerning given SOMMF’s recent earnings history. Two quarters ago, the company posted $0.1859 in EPS, demonstrating profitability. The swing to negative earnings suggests either higher costs, lower volumes, or one-time charges impacting the bottom line. Investors should monitor management commentary on cost pressures and market conditions.

Revenue Projection Context

The $3.88 billion revenue estimate sits between recent quarterly results. The company reported $3.90 billion last quarter and $3.63 billion two quarters prior. This suggests relatively stable demand across SOMMF’s chemical segments, though growth remains muted. The chemicals sector faces ongoing pricing pressure and input cost volatility.

Comparison to Historical Performance

Looking at the past four quarters, SOMMF’s earnings have been volatile. The company posted $0.1859 EPS, then $-0.01909, followed by $0.04201. This inconsistency reflects cyclical industry dynamics and operational variability. The current negative estimate continues this unpredictable trend.

Beat or Miss Probability Assessment

Based on SOMMF’s historical earnings patterns, the company has shown mixed results meeting or exceeding analyst expectations. Recent quarters reveal a pattern of modest beats and significant misses, making prediction difficult.

Historical Beat/Miss Pattern

Two quarters ago, SOMMF beat revenue estimates by $168 million, delivering $3.90 billion versus the $3.73 billion estimate. However, the EPS estimate of $-0.01107 was beaten with actual results of $0.1859, a substantial positive surprise. This demonstrates management’s ability to control costs when focused. The most recent quarter showed a revenue miss of $268 million, with actual revenue of $3.63 billion below the $3.90 billion estimate.

Likelihood of Beat This Quarter

Given the negative EPS estimate, beating expectations requires either smaller losses or unexpected profitability. The revenue estimate of $3.88 billion appears reasonable based on recent trends. A beat would require operational improvements or favorable one-time items. Management’s track record suggests modest upside potential, though negative earnings make surprises less likely.

Key Variables Affecting Results

Chemical prices, production volumes, and currency fluctuations will drive results. SOMMF’s exposure to global markets means exchange rates matter significantly. Input costs for raw materials remain a critical factor. Any supply chain disruptions or demand weakness in key markets could pressure margins further.

Financial Health and Key Metrics

SOMMF’s balance sheet shows moderate leverage with a debt-to-equity ratio of 1.19. The company maintains adequate liquidity with a current ratio of 1.57, indicating solid short-term financial health. Operating margins have compressed to 6.4%, down from historical levels, reflecting industry challenges.

Profitability Trends

Net profit margin stands at 4.1%, a concerning level for a diversified chemical company. Return on equity of 10.4% remains respectable but shows declining efficiency. The company’s gross margin of 29.8% provides some cushion, though operating expenses consume significant revenue. Management must demonstrate cost discipline to restore profitability.

Cash Flow and Capital Allocation

Operating cash flow per share reached $124.85, demonstrating the company’s ability to generate cash despite earnings volatility. Free cash flow per share of $56.86 supports dividend payments of $13.80 per share. The dividend yield of 2.6% attracts income-focused investors, though sustainability depends on earnings recovery.

Valuation Metrics

SOMF trades at a PE ratio of 8.88, below the broader market average, suggesting undervaluation or justified caution. The price-to-sales ratio of 0.36 indicates the market values the company conservatively. Book value per share of $773.95 means the stock trades at 0.84 times book value, suggesting potential value for patient investors.

What Investors Should Watch

The earnings call will provide crucial insights into management’s outlook and strategic direction. Investors should focus on segment performance, margin trends, and guidance for coming quarters.

Segment Performance Breakdown

SOMF operates five main segments: Essential Chemicals & Plastics, Energy & Functional Materials, IT-Related Chemicals, Health & Crop Sciences, and Pharmaceuticals. Management commentary on each segment’s profitability and growth prospects matters significantly. The IT-related chemicals segment, serving semiconductor and display markets, faces cyclical demand. Health and crop sciences provide more stable cash flows.

Margin Recovery Plans

With operating margins compressed, management must articulate a path to profitability. Cost reduction initiatives, pricing actions, or product mix improvements could drive recovery. Investors should listen for concrete actions rather than vague promises. Any guidance on margin expansion timelines will influence stock direction.

Capital Expenditure and R&D Investment

Capital intensity in chemicals requires ongoing investment. Management’s spending plans on new capacity or technology development signal confidence in future demand. R&D spending on advanced materials and sustainable chemistry could differentiate SOMMF from competitors. Meyka AI rates SOMMF with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

Sumitomo Chemical faces a challenging earnings report with negative EPS estimates signaling margin pressure across its chemical portfolio. The $3.88 billion revenue estimate suggests stable demand, but profitability remains the critical concern. Historical volatility in earnings makes prediction difficult, though the company’s recent revenue beat suggests operational competence. With a B+ Meyka grade and conservative valuation at 8.88 PE, SOMMF appeals to value investors willing to tolerate near-term earnings weakness. The key question is whether management can articulate a credible path to margin recovery. Investors should focus on segment trends, cost initiatives, and forward guidance d…

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.